beclometasone dipropionate + montelukast

This is a fixed-dose combination of two active pharmaceutical ingredients used in the management of asthma and allergic rhinitis: - **Beclometasone dipropionate** is an inhaled synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties. It acts primarily by binding to the glucocorticoid receptor, suppressing airway inflammation, reducing bronchial hyperresponsiveness, and decreasing mucus production. - **Montelukast** is an oral leukotriene receptor antagonist that selectively blocks cysteinyl leukotriene D4 at the CysLT1 receptor in the lungs and bronchial tubes. This action reduces airway edema, smooth muscle contraction, and inflammation. The combination is used as maintenance therapy for patients whose asthma or allergic rhinitis symptoms are not adequately controlled with inhaled corticosteroids alone. Clinical studies have shown that adding montelukast to beclometasone improves lung function (FEV1), reduces daytime asthma symptoms, nocturnal awakenings, and improves overall control compared to monotherapy[1][2][5]. The combination does not replace fast-acting rescue medications for acute attacks.